Possible side effects of Fulvestrant/Fuxit and countermeasures

Fulvestrant (Fulvestrant), as an estrogen receptor degrader (SERD), is generally well tolerated, but it may still cause some side effects, mainly focusing on injection site reactions, systemic discomfort, and changes in liver function. The most common local reactions are pain and mild redness and swelling at the injection site, which usually resolve within a few hours to a few days after the injection. To reduce pain, apply ice or gently massage the injection area. Over-the-counter analgesics can be taken if necessary, but avoid affecting drug absorption.

In terms of systemic reactions, patients may experience symptoms such as nausea, bone or joint pain, back pain, fatigue, headache, and heat flashes. Most of these reactions are mild to moderate and can be alleviated by regular sleep, moderate exercise and hydration. For long-term bone pain, you can consult your doctor whether you need to supplement calcium and vitaminD, or perform drug analgesic treatment. Changes in liver function are another type of side effect that requires attention, and some patients may have elevated serum aminotransferases (ALT, AST). Therefore, liver function indicators should be monitored regularly before and during treatment. If obvious abnormalities occur, the dosage should be adjusted or the medication should be temporarily discontinued according to the doctor's recommendations.

In addition, fulvestrant may in rare cases cause an increased risk of blood clots, allergic reactions, or general weakness. If you develop persistent high fever, rash, difficulty breathing or swelling of lower limbs during use, you should seek medical attention immediately. For elderly patients or patients with impaired liver and kidney function, they should be used with caution under the guidance of a doctor, and it may be necessary to extend the injection interval or reduce the dose.

In general, the side effects of fulvestrant can be effectively managed through early monitoring, moderate dose adjustment and local care. Its safety is better than traditional chemotherapy drugs, and it is suitable for long-term maintenance treatment and combined endocrine regimens. It provides a stable and controllable treatment experience for patients with HR-positive advanced stage breast cancer.

Reference materials:https://medlineplus.gov/druginfo/meds/a607031.html